)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Celyad Oncology
Celyad Oncology (CYAD) investor relations material
Celyad Oncology H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary23 Sep, 2026
Executive summary
Focus shifted to monetizing intellectual property after discontinuing R&D and clinical trials in 2022, with efforts to secure licensing or asset sale agreements.
Sale of the C-CathEZ catheter business to CellProthera completed in February 2026, with up to €5 million in milestone-based payments and future royalties.
Private placement of €0.5 million in July 2026 extended cash runway to mid Q2 2027.
Financial highlights
Net loss for H1 2026 was €1.2 million, a significant improvement from €3.7 million in H1 2025.
Operating loss for H1 2026 was €1.2 million, compared to €3.7 million in H1 2025.
Cash and cash equivalents stood at €0.1 million as of June 30, 2026, down from €1.7 million at year-end 2025.
Employee benefit expenses dropped to €0.4 million due to workforce reduction.
Other income increased due to gain on sale of the C-Cath business.
Outlook and guidance
Cash runway extended to mid Q2 2027 following the July 2026 private placement.
Additional funding required by mid Q2 2027; company is evaluating financing options including equity, debt, partnerships, or asset sales.
No assurance of securing further financing, indicating material uncertainty about going concern status.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Celyad Oncology
- Returned to profitability in 2025 via asset sales, but future depends on IP monetization and new funding.CYAD
H2 2025 - Net loss widened to €3.7M in H1 2025, with cash projected to last into Q4 amid ongoing risks.CYADH1 2025
- Net loss narrowed and cash runway secured as CAR T-cell platforms advance and partnerships pursued.CYADH1 2024
- Net loss narrowed and cash burn reduced as Celyad advanced CAR-T platforms but faces funding risks.CYADH2 2024
Next Celyad Oncology earnings date
H2 20261 Apr, 2027
Celyad Oncology
Next Celyad Oncology earnings date
H2 20261 Apr, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Celyad Oncology SA is a Belgium-based clinical-stage biotechnology company focused on the development of cell therapy solutions for cancer. The company specializes in chimeric antigen receptor T-cell (CAR-T) therapies, leveraging proprietary technologies to develop allogeneic and autologous approaches for the treatment of solid and hematologic tumors. Celyad Oncology conducts research and clinical trials in collaboration with academic and industry partners. The company is headquartered in Mont-Saint-Guibert, Belgium, and its shares are listed on the Euronext Brussels and the NASDAQ.